# The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa

> **NCT02018692** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sheba Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DIETARY_SUPPLEMENT:** Alga Dunaliella Bardawil powder
- **DIETARY_SUPPLEMENT:** Placebo:Starch

## Key facts

- **NCT ID:** NCT02018692
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02018692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02018692, "The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02018692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*